Evaluation of Serum Mammaglobin as an Alternative Biomarker in the Diagnosis of Breast Tumors

Abstract

Introduction Breast cancer is the most common cancer in women in India and accounts for 14% of all cancers in women. Rise in mortality is due to lack of awareness and proper screening. Mammography and presently available serum biomarkers have low sensitivity and specificity. In our quest to identify a better biomarker, we studied mammaglobin (MAM) in patients with breast cancer and benign breast tumors.

Aim To evaluate serum mammaglobin in breast cancer patients and compare it with benign breast tumor patients and healthy controls. To compare it with existing biomarkers serum carcinoembryonic antigen (CEA) and cancer antigen 15–3 (CA 15–3). Materials and methods: This is a cross-sectional, case–control study of 77 subjects, of which 27 were breast cancer patients, 20 benign breast tumor patients, and 30 healthy controls. Serum CEA and CA15–3 were estimated by electrochemiluminescence immunoassay (ECLIA) and mammaglobin (MAM) by enzyme-linked immunosorbent assay (ELISA).

Results Mammaglobin and CEA levels were elevated in breast cancer patients, followed by benign breast tumors when compared with controls (P < 0.000001). Mammaglobin showed 81.5% sensitivity, 100% specificity, 100% positive predictive value (PPV), and 88.9% negative predictive value (NPV). CEA showed 88.9% sensitivity, 82.5% specificity, 77.4% PPV, and 91.7% NPV. The area under the curve was the highest for MAM (0.892), followed by CEA (0.889) and CA 15–3 (0.555). CA15–3 showed poor diagnostic efficacy. Combined receiver operating characteristic (ROC) curve of the biomarkers MAM and CEA had an AUC of 0.913.

Conclusion Mammaglobin proved to be an efficacious biomarker in diagnosing breast cancer.

Keywords

breast cancer - breast tumor - CA 15–3 - CEA - MAM - mammaglobin

Publikationsverlauf

Artikel online veröffentlicht:
17. August 2022

• References

• 1 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
• 2 Malvia S, Bagadi SA, Dubey US, Saxena S. Epidemiology of breast cancer in Indian women. Asia Pac J Clin Oncol 2017; 13 (04) 289-295
• 3 Al Joudi FS. Human mammaglobin in breast cancer: a brief review of its clinical utility. Indian J Med Res 2014; 139 (05) 675-685
• 4 Meng Q, Shi S, Liang C. et al. Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis. OncoTargets Ther 2017; 10: 4591-4598
• 5 Zuo L, Li L, Wang Q, Fleming TP, You S. Mammaglobin as a potential molecular target for breast cancer drug delivery. Cancer Cell Int 2009; 9: 8
• 6 Al-Joudi FS, Kaid FA, Ishak I, Mohamed N, Osman K, Alias IZ. Expression of human mammaglobin and clinicopathologic correlations in breast cancer: the findings in Malaysia. Indian J Pathol Microbiol 2011; 54 (02) 284-289
• 7 Bernstein JL, Godbold JH, Raptis G. et al. Identification of mammaglobin as a novel serum marker for breast cancer. Clin Cancer Res 2005; 11 (18) 6528-6535
• 8 Zehentner BK, Persing DH, Deme A. et al. Mammaglobin as a novel breast cancer biomarker: multigene reverse transcription-PCR assay and sandwich ELISA. Clin Chem 2004; 50 (11) 2069-2076
• 9 Galvis-Jiménez JM, Curtidor H, Patarroyo MA, Monterrey P, Ramírez-Clavijo SR. Mammaglobin peptide as a novel biomarker for breast cancer detection. Cancer Biol Ther 2013; 14 (04) 327-332
• 10 Abd El-Hafez ZA, Khaled SMI, Rizk M, El-Gammal YT. Assessment of human mammaglobin (hMAG) as a new marker for early diagnosis of breast cancer. Med J Cairo Univ 2018; 86: 1263-1270
• 11 Guadagni F, Ferroni P, Carlini S. et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res 2001; 7 (08) 2357-2362
• 12 Fejzić H, Mujagić S, Azabagić S, Burina M. Tumor marker CA 15-3 in breast cancer patients. Acta Med Acad 2015; 44 (01) 39-46